Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, REGN-2810(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13940MR)

This product GTTS-WQ13940MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Acute myeloid leukemia (AML) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, REGN-2810(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ13940MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13616MR IVTScrip™ mRNA-Anti-APP, R1450(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA R1450
GTTS-WQ13369MR IVTScrip™ mRNA-Anti-LRRC15, PR-1498487(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA PR-1498487
GTTS-WQ10559MR IVTScrip™ mRNA-Anti-IL23A, LY­3074828(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LY­3074828
GTTS-WQ2902MR IVTScrip™ mRNA-Anti-IL17RA, AMG827(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG827
GTTS-WQ5891MR IVTScrip™ mRNA-Anti-IL31RA, CIM 331(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CIM 331
GTTS-WQ15398MR IVTScrip™ mRNA-Anti-HAVCR2, TSR-022(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA TSR-022
GTTS-WQ4981MR IVTScrip™ mRNA-Anti-ITGA2B&ITGB3, C4G1(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA C4G1
GTTS-WQ8940MR IVTScrip™ mRNA-Anti-IL1RL2, IL2 fused to diphteria toxin(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IL2 fused to diphteria toxin
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW